Bernadine Healy | Academic Influence

Bernadine Healy's AcademicInfluence.com Rankings

Bernadine Healy

Medical

#107

World Rank

#176

Historical Rank

#55

USA Rank

Cardiology

#20

World Rank

#20

Historical Rank

#5

USA Rank

medical Degrees

Download Badge

Medical

Bernadine Healy's Degrees

Doctorate Medicine Harvard University

Why Is Bernadine Healy Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Bernadine Patricia Healy was an American cardiologist and the first female director of the National Institutes of Health . During her career, Healy held leadership positions at the Johns Hopkins University, the Cleveland Clinic, Ohio State University, and Harvard University. She was also president of both the American Red Cross and the American Heart Association. She was health editor and columnist for U.S. News & World Report and a well-known commentator in the news media on health issues.

(See a Problem?)

Bernadine Healy's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 (2020) (982)
The Yentl syndrome. (1991) (486)
Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. (2009) (348)
Human polymorphism at microRNAs and microRNA target sites. (2013) (330)
Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. (2015) (321)
Effect of fresh‐frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities (2006) (320)
IL2RA Genetic Heterogeneity in Multiple Sclerosis and Type 1 Diabetes Susceptibility and Soluble Interleukin-2 Receptor Production (2009) (244)
Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis (2013) (226)
Smoking and disease progression in multiple sclerosis. (2009) (217)
A Second Chance to Get Causal Inference Right: A Classification of Data Science Tasks (2018) (209)
Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. (2015) (198)
Mechanically adaptive intracortical implants improve the proximity of neuronal cell bodies (2011) (169)
Collaborative care for depression and anxiety disorders in patients with recent cardiac events: the Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized clinical trial. (2014) (162)
Feasibility and utility of positive psychology exercises for suicidal inpatients. (2014) (145)
Soluble IL-2RA Levels in Multiple Sclerosis Subjects and the Effect of Soluble IL-2RA on Immune Responses1 (2009) (137)
Relationships between positive psychological constructs and health outcomes in patients with cardiovascular disease: A systematic review. (2015) (133)
A probiotic modulates the microbiome and immunity in multiple sclerosis (2018) (130)
Clinical and MRI phenotype of children with MOG antibodies (2016) (128)
Deep Gray Matter Involvement on Brain MRI Scans Is Associated with Clinical Progression in Multiple Sclerosis (2009) (126)
Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life. (2012) (126)
Exploration of machine learning techniques in predicting multiple sclerosis disease course (2017) (117)
The association between cognitive impairment and quality of life in patients with early multiple sclerosis (2010) (116)
Brain MRI Lesion Load at 1.5T and 3T versus Clinical Status in Multiple Sclerosis (2011) (114)
Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. (2019) (105)
Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis (2018) (98)
Effect of gender on late-onset multiple sclerosis (2012) (91)
Impact of a Depression Care Management Program for Hospitalized Cardiac Patients (2011) (85)
Investigation of probiotics in multiple sclerosis (2018) (84)
Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study (2009) (84)
Cognitive deterioration in patients with early multiple sclerosis: a 5-year study (2011) (80)
3 T MRI relaxometry detects T2 prolongation in the cerebral normal-appearing white matter in multiple sclerosis (2009) (78)
Distal pancreatectomy with splenic preservation revisited. (2006) (75)
Brain regional lesion burden and impaired mobility in the elderly (2011) (69)
CTLA4Ig treatment in patients with multiple sclerosis (2008) (69)
Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis (2018) (66)
Intensive Mutagenesis of the Nisin Hinge Leads to the Rational Design of Enhanced Derivatives (2013) (65)
Evaluation of an Online Platform for Multiple Sclerosis Research: Patient Description, Validation of Severity Scale, and Exploration of BMI Effects on Disease Course (2013) (65)
The Balance of Power in International History (1973) (62)
Innovators for the 21st century: will we face a crisis in biomedical-research brainpower? (1988) (61)
Seasonal prevalence of MS disease activity (2010) (60)
Approaches to Normalization of Spinal Cord Volume: Application to Multiple Sclerosis (2012) (57)
The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis (2019) (57)
Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. (2008) (56)
A 3T MR Imaging Investigation of the Topography of Whole Spinal Cord Atrophy in Multiple Sclerosis (2011) (54)
Optimizing a Positive Psychology Intervention to Promote Health Behaviors After an Acute Coronary Syndrome: The Positive Emotions After Acute Coronary Events III (PEACE-III) Randomized Factorial Trial (2018) (52)
Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity (2017) (52)
Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis (2014) (51)
Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort (2016) (49)
Conflict-of-interest guidelines for a multicenter clinical trial of treatment after coronary-artery bypass-graft surgery. (1989) (48)
Identification of MS-specific serum miRNAs in an international multicenter study (2018) (47)
Effect of vitamin D on MS activity by disease-modifying therapy class (2015) (46)
Text Message Interventions for Physical Activity: A Systematic Review and Meta-Analysis. (2019) (46)
Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis (2015) (45)
Depression and fatigue in patients with multiple sclerosis (2017) (44)
Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis (2013) (44)
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development (2014) (43)
Metabolic and Endocrine correlates of cognitive function in healthy young women (2012) (43)
Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients (2016) (41)
Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time? (2013) (41)
Nisin J, a Novel Natural Nisin Variant, Is Produced by Staphylococcus capitis Sourced from the Human Skin Microbiota (2019) (41)
A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. (2010) (40)
Patients report worse MS symptoms after menopause: findings from an online cohort. (2015) (40)
Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments (2011) (38)
Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis (2016) (38)
Medulla Oblongata Volume: A Biomarker of Spinal Cord Damage and Disability in Multiple Sclerosis (2008) (38)
Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis (2016) (37)
7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions (2019) (37)
Usefulness of a Positive Psychology-Motivational Interviewing Intervention to Promote Positive Affect and Physical Activity After an Acute Coronary Syndrome. (2019) (37)
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy (2014) (34)
Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis (2017) (33)
The Positive Emotions after Acute Coronary Events behavioral health intervention: Design, rationale, and preliminary feasibility of a factorial design study (2017) (32)
Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus (2013) (31)
MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis (2014) (30)
Patient Health Questionnaire-9 score and adverse cardiac outcomes in patients hospitalized for acute cardiac disease. (2013) (30)
No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50 (2013) (30)
Influence of Personality on the Relationship Between Gray Matter Volume and Neuropsychiatric Symptoms in Multiple Sclerosis (2013) (30)
Diet pattern and prodromal features of Parkinson disease (2020) (29)
CTLA4Ig treatment in patients with multiple sclerosis An open-label, phase 1 clinical trial (2008) (28)
Treatment satisfaction in multiple sclerosis. (2014) (28)
Longitudinal BMI trajectories in multiple sclerosis: Sex differences in association with disease severity. (2016) (28)
Cost-Effectiveness of a Collaborative Care Depression and Anxiety Treatment Program in Patients with Acute Cardiac Illness. (2016) (28)
Increased leptin and A-FABP levels in relapsing and progressive forms of MS (2013) (26)
Relationship of optimism and suicidal ideation in three groups of patients at varying levels of suicide risk. (2016) (25)
Fluctuations in appraisal over time in the context of stable versus non-stable health (2014) (25)
Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models (2015) (24)
The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis (2012) (24)
T1- vs. T2-based MRI measures of spinal cord volume in healthy subjects and patients with multiple sclerosis (2015) (24)
Temporal association of sNfL and gad‐enhancing lesions in multiple sclerosis (2020) (24)
Quantification of Global Cerebral Atrophy in Multiple Sclerosis from 3T MRI Using SPM: The Role of Misclassification Errors (2014) (23)
Disease modeling in multiple sclerosis: Assessment and quantification of sources of variability in brain parenchymal fraction measurements (2010) (23)
Social support in multiple sclerosis: Associations with quality of life, depression, and anxiety. (2020) (22)
Comparison of analysis approaches for phase III clinical trials in amyotrophic lateral sclerosis (2012) (22)
Data science is science's second chance to get causal inference right: A classification of data science tasks (2018) (22)
Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. (2019) (22)
Associations Between Psychological Constructs and Cardiac Biomarkers After Acute Coronary Syndrome (2017) (22)
An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2 (2014) (22)
Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis (2015) (21)
Perceptions of product advantage, NPD and organisational performance (2014) (21)
The Loyalty Continuum: Differentiating Between Stages of Loyalty Development (2014) (21)
Evaluating the Association between Enlarged Perivascular Spaces and Disease Worsening in Multiple Sclerosis (2018) (21)
Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing–remitting multiple sclerosis (2009) (21)
Second Primary Neoplasms in Patients With Uveal Melanoma: A SEER Database Analysis. (2016) (20)
History of fatigue in multiple sclerosis is associated with grey matter atrophy (2019) (19)
HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study (2011) (19)
Reserve and Reserve-building activities research: key challenges and future directions (2016) (19)
Improving the quality of mental health care in Multiple Sclerosis (2013) (19)
One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis (2011) (19)
A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis (2017) (18)
The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS (2015) (18)
On gene patenting. (1992) (18)
Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression (2020) (18)
Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis (2018) (18)
A method for evaluating treatment switching criteria in multiple sclerosis (2010) (17)
Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis (2018) (17)
Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. (2019) (17)
Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count. (2018) (16)
Access to Preventive Health Care in Severely Disabled Women with Multiple Sclerosis. (2015) (16)
The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. (2017) (16)
Time between expanded disability status scale (EDSS) scores. (2019) (16)
Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: A longitudinal study (2012) (15)
The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis (2016) (15)
Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis (2017) (15)
Age Differences in the Use of Health Information Technology Among Adults in the United States: An Analysis of the Health Information National Trends Survey (2020) (15)
Aberrant expression of USF2 in refractory rheumatoid arthritis and its regulation of proinflammatory cytokines in Th17 cells (2020) (14)
Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. (2017) (14)
Altruism and health outcomes in multiple sclerosis: The effect of cognitive reserve (2013) (14)
A Positive Psychology–Motivational Interviewing Intervention to Promote Positive Affect and Physical Activity in Type 2 Diabetes: The BEHOLD-8 Controlled Clinical Trial (2020) (14)
MRI phenotypes in MS (2019) (14)
An exploration of product advantage and its antecedents in SMEs (2017) (13)
The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis (2018) (13)
Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis (2018) (13)
Patient reported outcomes in benign multiple sclerosis (2011) (13)
Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines (2018) (12)
Adipokines are associated with pediatric multiple sclerosis risk and course. (2019) (12)
A positive psychology-motivational interviewing program to promote physical activity in type 2 diabetes: The BEHOLD-16 pilot randomized trial. (2020) (12)
Hidden Markov models for settings with interval-censored transition times and uncertain time origin: application to HIV genetic analyses. (2007) (12)
Removing Confounding Factors via Constraint Based Clustering: An Application to Finding Homogeneous Groups of Multiple Sclerosis Patients (2013) (12)
Feasibility and preliminary efficacy of a positive psychology-based intervention to promote health behaviors in heart failure: The REACH for Health study. (2020) (12)
The Effect of Fingolimod on Conversion of Acute Gadolinium‐Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis (2015) (11)
Computerized Cognitive Behavioral Therapy for Treatment of Depression in Multiple Sclerosis: A Narrative Review of Current Findings and Future Directions. (2019) (11)
A novel classification of fatigue in multiple sclerosis based on longitudinal assessments (2020) (11)
Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis (2019) (11)
Randomized controlled trial of a well-being intervention in cardiac patients. (2019) (11)
Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies (2011) (11)
Patient-reported outcomes in multiple sclerosis: Relationships among existing scales and the development of a brief measure. (2015) (10)
Power, balance of power, and status in nineteenth century international relations (1974) (10)
Risk attitudes and risk perceptions in individuals with multiple sclerosis (2016) (10)
Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity (2020) (10)
Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis (2017) (10)
Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study (2020) (10)
Is it better to cultivate positive affect or optimism? Predicting improvements in medical adherence following a positive psychology intervention in patients with acute coronary syndrome. (2019) (10)
A Metabolomics Analysis of Adiposity and Advanced Prostate Cancer Risk in the Health Professionals Follow-Up Study (2020) (9)
Progression rates and sample size estimates for PPMS based on the CLIMB study population (2015) (9)
Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients (2019) (9)
Modeling disease‐state transition heterogeneity through Bayesian variable selection (2009) (9)
A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis (2017) (9)
Effect of pregnancy loss on MS disease activity (2018) (9)
Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint (2010) (9)
Hearing on the possible uses and misuses of genetic information. (1992) (9)
Is this your father's NIH? And other strategic questions. (1992) (9)
An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis (2016) (8)
Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate (2018) (8)
State gratitude for one’s life and health after an acute coronary syndrome: Prospective associations with physical activity, medical adherence and re-hospitalizations (2019) (7)
Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis (2020) (7)
Identification of a predominant cognitive phenotype in patients with multiple sclerosis (2020) (7)
Argon Ion Laser Induced Tissue Fluorescence: Clinical Spectroscopic Studies (1988) (7)
Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma. (2019) (7)
MRI activity in MS and completed pregnancy (2020) (7)
The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis (2016) (7)
Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis (2011) (7)
Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy (2014) (7)
The NIH and numbers: a vital concern's concern. (1985) (7)
Does timeframe adjustment of the Life Orientation Test-Revised assess optimism as a state? (2019) (6)
Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis (2015) (6)
Shattuck Lecture--NIH and the bodies politic. (1994) (5)
Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson's Disease. (2020) (5)
A hundred million trees : the story of N.Z. Forest Products Ltd (1982) (5)
Positive psychology interventions in patients with medical illness: What predicts improvement in psychological state? (2019) (5)
Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis (2018) (5)
Remarks for the RAC Committee meeting of January 14, 1993, regarding compassionate use exemption. (1993) (5)
Food allergies are associated with increased disease activity in multiple sclerosis (2018) (5)
Exploring the feasibility and impact of positive psychology-motivational interviewing interventions to promote positive affect and physical activity in type 2 diabetes: design and methods from the BEHOLD-8 and BEHOLD-16 clinical trials (2020) (5)
Short Report: A Pilot Study of a Group Positive Psychology Intervention for Patients with Multiple Sclerosis. (2017) (5)
Spinal Cord as an Adjunct to Brain Magnetic Resonance Imaging in Defining "No Evidence of Disease Activity" in Multiple Sclerosis. (2017) (5)
Agreement analysis comparing iPad LCVA and Sloan testing in multiple sclerosis patients (2018) (4)
Accommodating Uncertainty in a Tree Set for Function Estimation (2008) (4)
The Dingell hearings on scientific misconduct. Blunt instruments indeed. (1993) (4)
Tocilizumab in Covid-19. Reply. (2020) (4)
Developing a Psychological-Behavioral Intervention in Cardiac Patients Using the Multiphase Optimization Strategy: Lessons Learned From the Field. (2019) (4)
Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study (2013) (3)
Predicting Clinical Course (2012) (3)
Combining Cross‐Sectional and Prospective Data Methods to Improve Transition Parameter Estimation for Characterizing the Accumulation of HIV‐1 Drug Resistance Mutations (2007) (3)
Predictors of completion of a psychological-behavioral intervention in acute coronary syndrome patients. (2018) (3)
Cortical Thickness Measurements from 1.5T vs. 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis (P4.179) (2016) (3)
Whole‐brain atrophy assessed by proportional‐ versus registration‐based pipelines from 3T MRI in multiple sclerosis (2018) (3)
Addressing Human Subjectivity via Transfer Learning: An Application to Predicting Disease Outcome in Multiple Sclerosis Patients (2014) (3)
Domain Induced Dirichlet Mixture of Gaussian Processes: An Application to Predicting Disease Progression in Multiple Sclerosis Patients (2015) (3)
Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis. (2020) (3)
Unbiased treatment effect estimates by modeling the disease process of multiple sclerosis (2009) (2)
Abstracts from the ASENT 2010 annual meeting March 4–6, 2010 (2010) (2)
Effects of Red Meat Diet Restriction on Multiple Sclerosis Severity (P1.404) (2016) (2)
Lantibiotic-related research and the application thereof. (2010) (2)
Off-Label Use of Recombinant FVIIa: Clinical Characteristics That May Influence Outcomes. (2005) (2)
Association between low testosterone and brain atrophy in men multiple sclerosis. (S38.006) (2015) (2)
Circulating microRNAs as Biomarkers for Disease Staging in MS (S11.005) (2013) (2)
Treatment strategy for coronary artery disease: a balancing act. (1990) (2)
Joint assessment of dependent discrete disease state processes (2017) (2)
The optimal gestational age for twin delivery (2005) (2)
A comprehensive evaluation of serum microRNAs as potential biomarkers in multiple sclerosis (P1.390) (2016) (2)
Differential Effects of Vitamin D in GA- versus IFN-Treated MS Patients (I7-1.004) (2014) (2)
Post-MI cardiac remodeling: new perspectives. (1991) (1)
Return to College After a First Episode of Psychosis (2020) (1)
A Pilot Study to Assess At-Home Speed of Processing Training for Individuals with Multiple Sclerosis (2019) (1)
The male 2D:4D digit ratio: a proxy for prenatal androgen exposure and a risk biomarker for multiple sclerosis. (S38.005) (2015) (1)
Angioplasty versus surgery: how best to revascularize the myocardium (1987) (1)
Quantification of callosal widths using Conformal Mapping : Application to Multiple Sclerosis (2008) (1)
An At-home Positive Psychology Intervention for Individuals with Multiple Sclerosis: A Phase 1 Randomized Controlled Trial. (2020) (1)
Dimethyl fumarate versus interferon for treatment of relapsing-remitting multiple Sclerosis (P6.381) (2017) (1)
Whole Brain Volume Measured from 1.5T vs. 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis (P6.156) (2015) (1)
Abstract #4: Global vs. Regional Spinal Cord Atrophy in Multiple Sclerosis (2010) (1)
Cerebral leptomeningeal enhancement is common and associated with cortical and thalamic lesions in relapsing-remitting multiple sclerosis: A 7T MRI study (S31.002) (2019) (1)
The Contribution of Cortical Lesions to a Magnetic Resonance Disease Severity Scale in Multiple Sclerosis (P4.168) (2016) (1)
How product advantage influences new product performance: an empirical investigation on the nature of product advantage and its’ relationship with new product performance in small and medium-sized enterprises (2012) (1)
Abstracts from the ASENT 2008 Annual Meeting March 6–8, 2008 (2008) (1)
Clinical Predictors for Fingolimod (Gilenya) Treatment Response in Multiple Sclerosis Patients (P7.226) (2014) (1)
Study of serum microrna expression in amyotrophic lateral sclerosis patients: The challenge of selecting suitable internal control for normalization (2019) (1)
Quantitative MRI Phenotypes in Longitudinal Population of MS Patients. (2014) (1)
TECHNICAL FIELD OF THE INVENTION (2017) (0)
Longitudinal Study of Disease Burden and Complications in a Cohort of Multiple Sclerosis Patients over the Age of 65. (2019) (0)
An Observational Comparison Of Natalizumab & Fingolimod Using JCV Serology To Randomize Therapy (P7.205) (2014) (0)
CONGRESSIONAL RECORD — SENATE 4178 March 30 , 2000 (2016) (0)
Abstract #6: Magnetic Resonance Disease Severity Scale (MRDSS) for Patients with Multiple Sclerosis: A Longitudinal Study (2010) (0)
Association of Serum Neurofilament Biomarker Levels with Quality of Life and Healthcare Utilization in Patients with Multiple Sclerosis (1852) (2020) (0)
Quantification of Global Cerebral Gray Matter Atrophy in Multiple Sclerosis from 3T MRI (P03.056) (2012) (0)
Assessment of clinical definitions of conversion of relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis (P4.402) (2017) (0)
F.23. A Panel of Immunologic Biomarkers Can Discriminate Between Patients with Multiple Sclerosis and Healthy Individuals (2008) (0)
Allergies Are Associated with Increased Disease Activity in Multiple Sclerosis (P2.187) (2016) (0)
Clinical inflammatory activity associated with response to second-line treatments in multiple sclerosis (2013) (0)
Brain and Spinal Cord MRI Findings in Primary Progressive vs. Relapsing-Remitting Multiple Sclerosis (P4.170) (2016) (0)
Hormonal Associations in the Early Disease Course in Men with Relapsing Remitting Multiple Sclerosis (P02.128) (2013) (0)
Modeling PML Risk in JCV Sero-Negative Natalizumab-Treated MS Patients (P2.247) (2014) (0)
Factor Affecting Recovery from Acute Optic Neuritis in Multiple Sclerosis Patients (P2.260) (2014) (0)
Infusion of fresh-frozen plasma (FFP) had minimal effect on mild coagulation defects (2007) (0)
Clinical and MRI Phenotype of Children with MOG Antibodies (P2.240) (2014) (0)
A Phenome-wide Examination Uncovers the Comorbidity Burden in Severe Multiple Sclerosis (P1.118) (2015) (0)
Reply (2013) (0)
Response to Letter to the Editor: "Real-World Considerations for Applicability of Text Message Interventions for Promotion of Physical Activity". (2020) (0)
Impact of cortical lesions identified by routine 3T MRI imaging on cognitive performance of patients with multiple sclerosis (2013) (0)
In Vivo Assessment of Retinal Neuronal Layers in Multiple Sclerosis Patients (P2.259) (2014) (0)
Does Alcohol and Red Wine Consumption Play a Role in Multiple Sclerosis Disease Course? (P2.213) (2015) (0)
Structural Connectivity Shapes Patterns of Cortical Atrophy in Multiple Sclerosis (S2.006) (2017) (0)
Clinical and Immunologic Characterization of MRI-Defined Phenotypes in Multiple Sclerosis: a Longitudinal Study (P2.371) (2018) (0)
Menopause In A Longitudinal Clinical Cohort Of Women With Multiple Sclerosis. (P4.163) (2014) (0)
Longitudial follow-up of at-risk infants (1984) (0)
An MRI-Defined Measure of Cerebral Lesion Severity to Assess the Therapeutic Effect of Glatiramer Acetate in Multiple Sclerosis (P4.172) (2016) (0)
Menopause May Not Modulate Disease Course in Multiple Sclerosis (P06.183) (2012) (0)
A New Composite Scale Of MRI-Defined Disease Severity In Multiple Sclerosis (P6.118) (2014) (0)
A longitudinal study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis. (P6.170) (2015) (0)
Reply: To PMID 22987690. (2013) (0)
MRI Characteristics of Malignant Multiple Sclerosis (S50.001) (2012) (0)
Poster Abstract #14: Magnetic Resonance Disease Severity Scale (MRDSS) Predicts Clinical Progression in Multiple Sclerosis (2008) (0)
Discontinuation of Disease-Modifying Therapy for Patient with Relapsing-Remitting Multiple Sclerosis (2019) (0)
Sample Size Requirements for Treatment Effects Using Deep Gray Matter Volume from 3T MRI in Progressive Forms of Multiple Sclerosis (P4.173) (2016) (0)
Serum microRNAs Are Related to Brain MRI Lesions and Atrophy in Patients with Multiple Sclerosis (P4.140) (2016) (0)
Clinical Study Assessment of Definitions of Sustained Disease Progression in Relapsing-Remitting Multiple Sclerosis (2013) (0)
A time before dying. (2002) (0)
Abstract 046: PCSK9 Inhibitors in Familial Hypercholesterolemia: a Meta-analysis of 9 Randomized Controlled Trials (2017) (0)
Abstract #3: Converting from CIS to Definite Multiple Sclerosis: An Imaging Based Predictive Model (2010) (0)
Investigation Of Sex Differences In The Association Between Multiple Sclerosis Disease Severity And Hormonal Markers Of Vitamin D, Obesity, And Testosterone. (S24.003) (2014) (0)
Evaluation of the revised 2013 MS clinical course definitions in the CLIMB real world cohort (P5.190) (2015) (0)
Cerebral White and Grey Matter MRI Segmentation with Lesion In-Painting in Multiple Sclerosis (2010) (0)
Is Baseline MRI Predictive of Response to Fingolimod Treatment in Multiple Sclerosis? (P3.280) (2015) (0)
Quantitative MRI study of Pineal Gland in MS. (2016) (0)
Mechanical and Biological Treatment (MBT)– An Investigation into the role of MBT in meeting Ireland’s waste treatment obligations. (2010) (0)
THROMBOTIC COMPLICATIONS FOLLOWING FEMORAL VEIN CATHETERIZATION (1995) (0)
Quo vadis, NIH? The new director plots a course. (1991) (0)
Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis (2020) (0)
The Reasonableness Standard: Why School Strip Searches Require a More Definitive Legal Precedent (2010) (0)
Housing procedures and actuator and associated (2005) (0)
Bioengineering of nisin to enhance functionality against dairy pathogens (2014) (0)
A strategy for the NIH's continuing success (1991) (0)
Bioprotectants for control of the emerging food-borne pathogen Mycobacterium avium subspecies paratuberculosis (MAP) (2012) (0)
Adipokine Levels in Relapsing and Progressive Forms of Multiple Sclerosis (P02.077) (2012) (0)
What makes a cluster work? A narrative analysis (2012) (0)
Does early (treatment in) BENEFIT lead to late MS benefit? (2016) (0)
The mysteries of hope and healing. (2004) (0)
Social capital's role in relationship between organisation culture and information sharing (2012) (0)
High Percentage Biosolids Digestion with Innovative Low Energy Technology (2010) (0)
Lantibiotics: bioengineering and applications. (2017) (0)
Age Related Recovery from Acute Optic Neuritis in Multiple Sclerosis (P04.120) (2013) (0)
SME's and the Internationalization of Food Products SME's and the Internationalization of Food Products: Process and Procedure (0)
A framework for discussion of strategies for the NIH. (1992) (0)

This paper list is powered by the following services:

Other Resources About Bernadine Healy

en.wikipedia.org

What Schools Are Affiliated With Bernadine Healy?

Bernadine Healy is affiliated with the following schools:

Image Attributions

Image Source for Bernadine Healy